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CSF = colony-stimulating factor; ICAM-1 = intercellular adhesion molecule-1; IL = interleukin; MCP = macrophage chemoattractant protein; 
MMP = matrix metalloprotease; TAM = tumour-associated macrophage; VEGF(R) = vascular endothelial growth factor (receptor).
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Introduction
Infiltration of lymphocytes, macrophages, mast cells and
neutrophils is a hallmark of inflammatory, defense and
tissue repair reactions, which are often present in tumours
[1,2]. Various types of tumour-infiltrating lymphocytes,
including cytotoxic T cells, natural killer cells and lym-
phokine activated killer cells, are viewed as potential effec-
tors of antitumour immunity and may oppose tumour
expansion [3]. Tumour-associated macrophages (TAMs)
constitute a major component of the leucocytic infiltrate
[4], and activated macrophages have been shown to
possess both direct and indirect tumouricidal activity [5,6].
However, evidence increasingly suggests that these cells
may in fact symbiotically promote rather than inhibit
tumour growth and development.
Macrophages, lymphocytes and mast cells have all been
implicated in another host-dependent process, namely
that of angiogenesis [7–9]. Clinical studies have linked the
extent of immune/inflammatory cell infiltration with
increased blood vessel density and poor prognosis in
various types of cancer, suggesting that these cells may
contribute to tumour progression in large part by stimulat-
ing tumour neovascularization [10,11]. Several studies in
mice support these observations, and demonstrate a criti-
cal role for macrophage and mast cell infiltration in pro-
moting angiogenesis during the earliest stages of
neoplastic progression [9,12,13].
Molecular regulators of inflammatory cell
infiltration into tumours
The infiltration of host immune cells into tumours is regu-
lated by cues from the tumour microenvironment, in com-
bination with tumour-derived chemokines, which together
influence the adhesion, extravasation and migration of leu-
cocytes. Breast carcinomas are known to contain a high
proportion of infiltrating leucocytes, particularly TAMs.
Macrophages are a heterogeneous population of cells that
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Abstract
Breast cancer progression is associated with and dependent upon robust neovascularization. It is
becoming clear that tumour-associated ‘normal’ cells, such as immune/inflammatory cells, endothelial
cells and stromal cells, conspire with cancer cells in promoting this process. In particular, infiltrating
immune/inflammatory cells secrete a diverse repertoire of growth factors and proteases that enable
them to enhance tumour growth by stimulating angiogenesis and, as we suggest here, by promoting
‘tumour arteriogenesis’ – enlargement of feeding vessels supplying the expanding tumour capillary
bed. Macrophages and their chemoattractants (e.g. macrophage chemoattractant protein-1) are critical
for the arteriogenic process in ischaemia, and probably also in breast neoplasia. A better
understanding of these various cellular and molecular constituents of breast cancer neovascularization
may be useful in designing more effective therapies.
Keywords: angiogenesis, arteriogenesis, cancer, immunity, inflammation84
Breast Cancer Research    Vol 5 No 2 Yu and Rak
belong to the mononuclear phagocyte system and are
derived from blood-borne monocytes that migrate into
tissues, where they undergo final differentiation. Tumour
hypoxia is an important stimulus for extravasation of mono-
cytes [14], which migrate into the tumour tissue along gra-
dients of chemoattractants, and these TAMs become
immobilized in ischaemic, necrotic areas of tumours,
where they can remain for an extended time [15–18].
Many studies have linked increased TAM density to poor
prognosis in breast cancer [15,19–21], and in fact certain
genetic alterations that increase the malignancy of the
tumour may concomitantly increase the degree of
macrophage infiltration. A strong association has been
reported between HER-2, c-myc and  int-2 oncogene
amplification in breast tumour samples and the density of
lymphocyte infiltration of the tumour [22]. In inflammatory
breast cancer, expression of constitutively activated RhoC
oncoprotein is associated with concomitant upregulation
of both angiogenic (vascular endothelial growth factor
[VEGF]) and inflammatory (IL-6) cytokines, leading to the
formation of a specific type of inflammatory/angiogenic
stroma in this particularly aggressive form of disease [23].
Some of the tumour molecular alterations that increase
macrophage infiltration and macrophage-mediated angio-
genesis include increased expression of monocyte
chemoattractant protein (MCP)-1 and VEGF, both of which
are highly expressed in breast tumour cells. MCP-1, a
member of the C–C chemokine family, is involved in mono-
cyte and T-lymphocyte migration, and is secreted by many
human and murine tumour cells in addition to activated
stromal cells [24,25]. MCP-1 expression in tumour cells is
significantly correlated with the extent of TAM infiltration
[26,27], and in particular both MCP-1 and VEGF expres-
sion have been positively correlated with TAM infiltration,
angiogenesis and poor survival in breast cancer [28–30].
VEGF is a potent angiogenic growth factor that is over-
expressed in the majority of human cancers [31]. VEGF
produced by tumours promotes the proliferation, survival
and migration of endothelial cells by binding to its recep-
tors, namely VEGF receptor (VEGFR)-1 and VEGFR-2,
which are expressed on the endothelial cell surface.
However, in addition to these direct effects on endothelial
cells, VEGF also stimulates monocyte migration through
VEGFR-1 [32], which is expressed on monocytes and
macrophages, as well as on endothelial cells [33,34]. A
positive correlation between VEGF expression and degree
of macrophage infiltration has been observed in invasive
breast carcinoma [28,35] and other malignancies [36,37].
Placental growth factor and VEGF-C – two VEGF-related
tumour-derived growth factors – can also stimulate mono-
cyte chemotaxis [38,39]. Placental growth factor may also
act as a survival factor for both endothelial cells and
macrophages [40].
The other important factor responsible for increased
macrophage infiltration in breast cancer is the
macrophage colony-stimulating factor (CSF)-1; this is a
haematopoietic growth factor that regulates the prolifera-
tion, survival and differentiation of monocytes and
macrophages, which express the CSF-1 receptor [41].
Although it is secreted by many types of cells, increased
expression of CSF-1 occurs in breast tumours, where it
has been associated with high TAM infiltration and poor
prognosis [42–44]. The critical importance of CSF-1 pro-
duction, not only for macrophage recruitment but also for
tumour vascularization and progression, has also been
demonstrated in transgenic mouse models of breast
cancer [45,46].
Contribution of inflammatory cells to tumour
angiogenesis and lymphangiogenesis
Although tumour cells themselves promote the recruitment
and expansion of their own blood supply, tumour-associ-
ated immune/inflammatory cells can modify and contribute
to this process by supplying a repertoire of growth factors,
cytokines and proteases comparable to that secreted by
tumour cells themselves (summarized in Table 1). Inflam-
matory cells can produce a myriad of cytokines and
growth factors, many of which are proangiogenic, and
directly stimulate the migration and proliferation of
endothelial cells. For example, macrophages, mast cells
and neutrophils all secrete VEGF, IL-8 and transforming
growth factor-α. Some of these molecules, for example
VEGF, act not only on endothelial cells but also stimulate
migration of further inflammatory cells into the tumour,
potentially forming self-perpetuating positive feedback
loops. Factors that increase vascular permeability are also
proangiogenic because they promote deposition of fibrin,
providing a matrix favourable for endothelial cell and leuco-
cyte migration. For example, macrophage-derived VEGF,
substance P, platelet-activating factor and prostaglandins
induce vessel hyperpermeability [47]. Histamine, which is
stored and released by mast cells, has wide-ranging bio-
logical effects that include proangiogenic activity [48].
Inflammatory cells also secrete a variety of proteases that
degrade and remodel the extracellular matrix [47]. For
example, macrophages, mast cells, neutrophils and lym-
phocytes all secrete matrix metalloprotease (MMP)-9 – a
MMP that has emerged as an important modulator of
angiogenesis and tumour development [49]. Some of
these proteases (e.g. urokinase-type plasminogen activa-
tor and heparanase) release proangiogenic growth factors
(e.g. basic fibroblast growth factor) that are sequestered
by heparan sulphate proteoglycans in the extracellular
matrix. However, it should be kept in mind that MMPs,
including MMP-9, may also have an antiangiogenic effect
(at later stages) by processing the α3 chain of type IV col-
lagen to the angiogenesis inhibitor tumstatin [50]. Further-
more, at least one macrophage-derived protease, namely85
MMP-12 (metalloelastase), has been shown to generate
angiostatin, an endogenous angiogenesis inhibitor, from
its precursor – plasminogen [51]. MMP-7 and MMP-9
have also been shown to have angiostatin-converting
activity [52].
It should be noted that not all of the growth factors and
cytokines released by inflammatory cells are proangiogenic.
For example, macrophages secrete thrombospondin-1,
interferon-α and interferon-γ, which are antiangiogenic.
Many cytokines (e.g. transforming growth factor-β, IL-1β,
IL-6, tumour necrosis factor-α) are known to have
pleiotropic effects, stimulating angiogenesis under certain
conditions and inhibiting it under others [47]. It is not known
how the net proportion of the various proangiogenic or
antiangiogenic activities of macrophages and other inflam-
matory cells is regulated. However, this balance between
angiogenesis promoting, inhibiting and modulating influ-
ences at given times and locations in the tumour microenvi-
ronment clearly has a potential to determine the overall
course and dynamics of blood vessel formation.
Finally, immune/inflammatory cells may also promote
tumour lymphangiogenesis by secreting the lymphangio-
genic growth factors VEGF-C and VEGF-D [53,54]. The
formation of peritumoural lymphatic vessels, which in one
study correlated with the extent of TAM recruitment, repre-
sents an important conduit for the metastasis of tumours
to regional lymph nodes, with major implications for
patient prognosis [54,55].
‘Tumour arteriogenesis’: the possible role of
inflammatory cells
Although various processes that affect tumour microcir-
culation (both blood and lymphatic) have attracted con-
siderable attention and are being extensively
characterized at the molecular level, there has been
essentially no emphasis on the events that must implicitly
occur in the vascular tree upstream of the site of active
angiogenesis. The recruitment of large numbers of capil-
lary microvessels during tumour growth (as a result of
angiogenesis) considerably increases the intratumoural
capillary volume – a circumstance that would be
expected to require the concurrent expansion of
upstream arterioles and downstream venules (i.e. tumour
‘feeding vessels’). Indeed, such dilatations of feeding
vessels have been observed using angiography in cancer
patients [56]. This peritumoural remodelling and expan-
sion of pre-existing arteries and arterioles probably
involves processes similar to collateral vessel formation or
‘arteriogenesis’, which occurs during ischaemic limb or
heart disease. We postulate that an analogous process
of ‘tumour arteriogenesis’ must accompany angiogenic
expansion of the microvasculature, and hence such a
process could similarly be viewed as a rate-limiting and
targetable event during tumour expansion.
Monocytes are critical for the initiation of arteriogenesis
because they adhere to and invade endothelium activated
by the increased shear stress that results from large pres-
sure differences between perfused areas [57]. The
involvement of monocytes in arteriogenesis was discov-
ered by Schaper et al. in 1976 [58], shortly before their
role in angiogenesis in 1977 [7]. MCP-1 is once again
implicated in this process because it not only attracts
monocytes but also promotes their adhesion by inducing
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Table 1
Angiogenesis modulators produced by inflammatory/immune
cells
Cell type Activity Molecule Reference
Macrophages Proangiogenic VEGF [62]
TGF-α [63,64]
IL-8 [65]
bFGF [66]
TP [30,67]
PDGF [68]
Substance P [69]
Prostaglandins [70]
Antiangiogenic TSP-1 [71]
IFN-α [72]
IFN-γ [73]
Protease t-PA [74]
u-PA [75,76]
MMP-1, -2, -3, -7, [10,12,51]
-9 and -12
Mast cells Proangiogenic VEGF [77,78]
bFGF [79]
TGF-β [80]
TNF-α [81]
IL-8 [81]
Histamine [48]
Protease Chymase [9,81,82]
Tryptase [9,81]
MMP-9 [12]
Heparanase [83]
Neutrophils Proangiogenic VEGF [84]
IL-8 [84]
Antiangiogenic IL-12 [84]
IP-10 [85]
MIG [85]
Protease MMP-9 [86]
u-PA [86]
Elastase [12,87]
bFGF, basic fibroblast growth factor; IFN, interferon; IP, interferon
gamma inducible protein; MMP, matrix metalloprotease; PDGF,
platelet-derived growth factor; TGF, transforming growth factor; TNF,
tumour necrosis factor; TP, thymidine phosphorylase; t-PA, tissue-type
plasminogen activator; u-PA, urokinase-type plasminogen activator;
VEGF, vascular endothelial growth factor.86
them to upregulate Mac-1, the receptor for intercellular
adhesion molecule-1 (ICAM-1) that is expressed in acti-
vated endothelium [59]. Monocytes that adhere and then
invade the arteriolar wall subsequently promote collateral
artery growth by producing cytokines such as tumour
necrosis factor-α and basic fibroblast growth factor [60].
Studies of collateral growth in rabbits have shown that,
although prevention of monocyte adhesion (e.g. using anti-
bodies to ICAM-1) delays arteriogenesis, infusion of
MCP-1 or survival factors for monocytes (e.g. granulo-
cyte–macrophage CSF) accelerate the process [57].
Although VEGF has also been shown to stimulate collat-
eral growth, it now appears as though this positive effect
of VEGF on arteriogenesis may be due principally to its
effect on activating monocytes, stimulating their adhesion
to the endothelium and their transmigration through it [61].
Although the large ‘feeding vessels’ that supply tumour
vascular beds represent a potentially useful target for anti-
cancer therapies, the exact mechanisms by which they are
formed and recruited remains unknown. Again, the partici-
pation of monocytes/macrophages in this process has
never been examined; however, given their importance in
collateral formation, it is clear that they have the capability
to play a considerable role. These issues are being
actively pursued in our laboratory.
Conclusion
The recruitment of monocytes, macrophages and other
inflammatory cells to a tumour appears to be a common
denominator for the major processes involved in tumour
development and progression (Fig.1). Inflammatory cells
contribute to tumour angiogenesis by supplying proangio-
genic growth factors, cytokines and proteases. They also
contribute factors that promote the formation and enlarge-
ment of intratumoural or peritumoural lymphatic vessels,
eventually allowing a tumour to metastasize to distant
organs. Finally, they may also play a critical role in arterio-
genesis by promoting the growth of the larger vessels that
supply the expanding capillary bed, feeding the rapidly
growing tumour mass.
Is the recruitment of inflammatory cells a good target for
cancer therapy? It is important to keep in mind that
macrophages and other inflammatory cells, despite their
proangiogenic and protumour effects, may also participate
in antitumour immunosurveillance. The answer to this
question will probably depend on the type of tumour, on
the stage at which inflammatory cells provide the greatest
contribution during tumour progression, and on the nature
of their influence (tumour-promoting or inhibitory).
However, it could be speculated that simultaneously tar-
geting the proarteriogenic effects of macrophages and the
proangiogenic functions of endothelial cells may lead to
synergistic antitumour effects, and exploration of this pos-
sibility is therefore warranted.
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